FDA Approves TRYVIO — Idorsia Pharmaceuticals Ltd

Idorsia Pharmaceuticals Ltd announced on March 19, 2024, that the FDA granted approval for TRYVIO (aprocitentan) to treat pulmonary arterial hypertension, marking a significant validation of the company's pipeline that is expected to provide an important new option in the PH therapeutic landscape. The emboldened oral therapy aims to leverage a novel dual endothelin-1 receptor inhibition mechanism to address the current unmet need for better efficacy and tolerability in this patient population.